Rajeev Narayan, MD
Nephrology · San Antonio, TXNPI 1093805863
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $38,578 of the $57,026 with a category attached, or 67.7%. 26 manufacturers reported payments, led by GE HealthCare at 43.8% of the total. Reporting peaked in 2019 at $25,439 and has fallen 57.4% since, to $10,841 in 2025. Among nephrology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $471.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GE HealthCare$25K
- Medtronic$16K
- Merit Medical Systems Inc$14K
- Avenu Medical Inc.$418
- Amgen$301
- OPKO Pharmaceuticals, LLC$256
- plus $1K from 20 others
Across 5 payments — averaging $5202.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bard Peripheral Vascular, Inc.$26K
What the payments were for
- Consulting fees$38,57868%
- Food & beverage$2,8055%
- Education$600%
- Other$15,58227%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GE HealthCare | 1 | $24,978 |
| Medtronic(2 entities) | 14 | $15,979 |
| Merit Medical Systems Inc | 3 | $13,600 |
| Avenu Medical Inc. | 3 | $418 |
| Amgen(2 entities) | 17 | $301 |
| OPKO Pharmaceuticals, LLC | 17 | $256 |
| Otsuka America Pharmaceutical, Inc. | 9 | $175 |
| Vifor Pharma, Inc. | 8 | $163 |
| Calliditas Therapeutics US Inc. | 6 | $149 |
| Bayer | 5 | $126 |
| Nxstage Medical, Inc. | 1 | $124 |
| Abbott | 2 | $105 |
| AstraZeneca | 6 | $91 |
| Novo Nordisk | 4 | $85 |
| Ardelyx, Inc. | 4 | $81 |
| Novartis | 4 | $69 |
| Cormedix Inc. | 1 | $45 |
| Bard Peripheral Vascular, Inc. | 3 | $43 |
| Travere Therapeutics, Inc. | 3 | $42 |
| Akebia Therapeutics Inc | 2 | $41 |
| Mallinckrodt Enterprises LLC | 2 | $40 |
| Shield Therapeutics Inc | 2 | $37 |
| Aurinia Pharma U.S., Inc. | 1 | $27 |
| GSK | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $17 |
| W. L. Gore & Associates, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Peritoneal Dialysis Systems$13,600
- Ellipsys$12,011
- ELLIPSYS VASCULAR ACCESS SYSTEM$4,146
- Wrapsody Stent Graft$3,400
- NXSTAGE SYSTEM ONE$124
How this compares
$57,026 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 41 | $126,370 |
| OzempicSemaglutide | 76 | $80,839 |
| VelphoroSucroferric Oxyhydroxide | 13 | $43,590 |
| Sevelamer Carbonate | 33 | $20,895 |
| FarxigaDapagliflozin Propanediol | 12 | $18,391 |
| LokelmaSodium Zirconium Cyclosilicate | 25 | $17,950 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $16,111 |
| RayaldeeCalcifediol | 18 | $15,805 |
| ProsolParenteral Amino Acid 20% No.1 | 52 | $9,518 |
| Midodrine Hcl | 30 | $1,644 |
| Nifedipine ErNifedipine | 25 | $1,324 |
| Calcium Acetate | 15 | $1,314 |
| Losartan Potassium | 63 | $526 |
| Allopurinol | 65 | $443 |
| Calcitriol | 25 | $442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $85 | $80,83976 claims |
| AstraZenecaFarxiga, Lokelma | $91 | $36,34137 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $256 | $15,80518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 nephrology providers in Texas.
Other nephrology in San Antonio
- Luis VelezSan Antonio$505K
- Rashid SharafSan Antonio$340K
- Carl DukesSan Antonio$238K
- Pablo PergolaSan Antonio$164K
- Varshasb BroumandSan Antonio$118K
- Shweta BansalSan Antonio$89K
- Anwar GergesSan Antonio$50K
- Matthew SchaeferSan Antonio$46K
- Kumar SharmaSan Antonio$45K
- Gerardo ChicaSan Antonio$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.